Company: LRHC
Filing Date: 2025-09-25
Form Type: S-1
Source: 0001213900-25-091637
Chunk: 30

Company: La Rosa Holdings Corp.
Filing Date: 2025-09-25
Form: S-1
Chunk 30
---
 substantial number of our shares of common stock in the public market by the Selling
Stockholder and/or by our other existing securityholders, or the perception that those sales might occur, could depress the market price
of our shares of common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable
to predict the effect that such sales may have on the prevailing market price of our shares of common stock.

Risks Related to the Facility

It is not possible to predict the actual number of shares of common stock we may sell to the Selling Stockholder under the Facility, or the actual gross proceeds resulting from such sales.

Because the purchase price per share to be paid
by the Selling Stockholder for the shares of common stock that we may elect to sell to the Selling Stockholder under the Facility, if
any, will fluctuate based on the market prices of our common stock at the time we elect to sell shares to the Selling Stockholder pursuant
to the Facility, if any, it is not possible for us to predict, as of the date of this Prospectus and prior to any such sales, the number
of shares of common stock that we will sell to the Selling Stockholder under the Facility, the purchase price per share that the Selling
Stockholder will pay for shares purchased from us under the Facility, or the aggregate gross proceeds that we will receive from those
purchases by the Selling Stockholder under the Facility.

<div align='center'>15</div>

The Company cannot effect any sales under the
Facility and the Selling Stockholder will not have any obligation to purchase shares of our common stock under the Facility to the extent
that after giving effect to such purchase and sale the aggregate number of shares of common stock issued under the Facility together with
any shares of common stock issued in connection with any other transaction that may be considered part of the same series of transactions,
where the number of shares issued would exceed the number of shares representing 19.99% of the issued and outstanding shares of common
stock as of the date of the Facility (the “Exchange Cap”), unless the Company has obtained stockholder approval as required
for issuance of common stock in excess of the Exchange Cap, in accordance with applicable rules of Nasdaq. Accordingly, the Company may
not have access to the right to sell the full Commitment Amount (as defined below) to the Selling Stockholder. As of September 24, 2025,
there were 1,224,640 shares of common